Andrew Cooper

Q: What is Andrew Cooper's success rate?

Andrew Cooper currently has a success rate of 100.

Q: What is the average return of Andrew Cooper's calls?

Their stock ratings have generated an average return of 22.12752572610074.

Raymond James | Healthcare

Andrew Cooper is an analyst from Raymond James specializing in the Healthcare sector. Ranked #1101 out of 4771 analysts, they have issued 5 stock ratings with a success rate of 100.00% and an average return of 22.13%.

With 5 ratings to date, Andrew Cooper is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 100.00% and an average return of 22.13%, highlighting promising potential as their track record develops further.

#1101

Out of 4771

Total Ratings

+100.00%

Success Rate

+22.13%

Average Return

Recent Ratings Analysis

HAE

Buy

Sep 03, 2026

Target

$125.00

Current

$101.06

Performance

-1.74%

Andrew Cooper rated HAE as Outperform on Sep 03, 2026, setting a price target of 125. Shares have remained stable near 101.06, leaving the 125 target still in play.

AZTA

Buy

Nov 25, 2025

Target

$45.00

Current

$30.18

Performance

-20.79%

On Nov 25, 2025, AZTA was given a Outperform rating by Andrew Cooper, with a target price of 45. Despite the Buy call, shares fell from 30.18 to 30.18, challenging the optimistic stance.

ITGR

Buy

Oct 24, 2025

Target

$95.00

Current

$126.05

Performance

72.88%

ITGR received a Outperform rating from Andrew Cooper on Oct 24, 2025, aiming for 95. Momentum has favored the Buy call, with shares climbing from 126.05 to 126.05, rewarding those who trusted the recommendation.

HOLX

Hold

Oct 22, 2025

Target

—

Current

$76.01

Performance

2.81%

On Oct 22, 2025, Andrew Cooper published a Market Perform outlook on HOLX, with a target of null. Sideways action left the Hold view intact, with no major move since 76.01.

AVTR

Buy

Oct 16, 2025

Target

$16.00

Current

$14.88

Performance

2.13%

Andrew Cooper on Oct 16, 2025 assigned AVTR a Outperform rating, with a price target of 16. The recommendation remains pending validation as shares consolidate around 14.88.

GH

Buy

Jul 31, 2025

Target

$61.00

Current

$159.03

Performance

288.07%

On Jul 31, 2025, Andrew Cooper reaffirmed GH with a Outperform rating, targeting 61. The recommendation was supported by strong follow-through as the stock rose from 159.03 to 159.03.

RVTY

Buy

Jul 29, 2025

Target

$115.00

Current

$120.94

Performance

28.02%

RVTY was rated Outperform by Andrew Cooper on Jul 29, 2025, with a price objective of 115. A bullish response from the market helped close the gap of -5.94 to the target.

TMO

Buy

Jul 24, 2025

Target

$535.00

Current

$603.18

Performance

26.98%

On Jul 24, 2025, Andrew Cooper initiated coverage on TMO with a Outperform rating and target of 535. The stock’s climb of 26.98% since the call highlights the foresight in the rating.

UFPT

Hold

Mar 28, 2025

Target

—

Current

$277.40

Performance

39.17%

Andrew Cooper issued a Market Perform recommendation for UFPT on Mar 28, 2025, price target set at null. A neutral call gave way to stronger-than-expected performance, closing in on null.

MYGN

Buy

Feb 25, 2025

Target

$19.00

Current

$3.36

Performance

-71.38%

On Feb 25, 2025, MYGN was evaluated by Andrew Cooper, who gave a Outperform rating and target of 19. Investors saw limited payoff as shares fell short of the 19 target.

DHR

Hold

Feb 03, 2025

Target

—

Current

$200.58

Performance

-6.38%

Andrew Cooper rated DHR as Market Perform on Feb 03, 2025, setting a price target of null. The cautious Hold call aligned with subsequent weakness, as shares slipped 6.38%.

EXAS

Hold

Sep 26, 2024

Target

—

Current

$104.91

Performance

54.42%

On Sep 26, 2024, EXAS was given a Market Perform rating by Andrew Cooper, with a target price of null. The stock rallied from 104.91 to 104.91 after the Hold rating, surprising to the upside.

CDNA

Hold

May 13, 2024

Target

—

Current

$50.02

Performance

233.91%

CDNA received a Market Perform rating from Andrew Cooper on May 13, 2024, aiming for null. Investors saw gains of 233.91% that the cautious stance didn’t fully capture.

Frequency Asked Questions

Who is Andrew Cooper?

Andrew Cooper is an analyst from Raymond James specializing in the Healthcare sector.

What is Andrew Cooper's success rate?

Andrew Cooper currently has a success rate of +100.00%.

How many ratings has Andrew Cooper issued?

Andrew Cooper has issued 5 stock ratings so far.

What is the average return of Andrew Cooper's calls?

Their stock ratings have generated an average return of +22.13%.

What is Andrew Cooper's ranking?

Andrew Cooper is ranked #1101 out of 4771 analysts.

What types of ratings does Andrew Cooper give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Andrew Cooper?

You can follow Andrew Cooper by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Andrew Cooper?

Their latest rating was a Buy on HAE issued on 2026-09-03.